Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | MITF | O75030 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3089382 | 0.95 | PIK3CD (0.53) | ALDH1A1POLBMAPTMAPK1L3MBTL1 | |
| SCHEMBL16037273 | 0.90 | MAPT (0.53) | ALDH1A1POLBMAPTMAPK1L3MBTL1 | |
| SCHEMBL17508432 | 0.87 | MAPT (0.47) | ALDH1A1POLBMAPTMAPK1L3MBTL1 | |
| SCHEMBL17610011 | 0.87 | MAPT (0.46) | ALDH1A1POLBMAPTMAPK1L3MBTL1 | |
| SCHEMBL29465027 | 0.87 | MAPT (0.46) | ALDH1A1POLBMAPTMAPK1L3MBTL1 | |
| SCHEMBL7000713 | 0.87 | MAPT (0.47) | ALDH1A1POLBMAPTMAPK1L3MBTL1 | |
| SCHEMBL7513519 | 0.85 | USP1 (0.45) | ALDH1A1POLBMAPTMAPK1L3MBTL1 | |
| SCHEMBL16366912 | 0.83 | PDE1B (0.46) | ALDH1A1POLBMAPTMAPK1L3MBTL1 | |
| SCHEMBL3084224 | 0.78 | PDE1A (0.52) | ALDH1A1ADORA3MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL556004 | 0.77 | ALDH1A1 (0.66) | ALDH1A1POLBMAPTMAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220089597-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2022-03-24 | — | — | US | disclosed |
| US-20210309663-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2021-10-07 | — | — | US | disclosed |
| US-20210309663-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2021-10-07 | — | — | US | disclosed |
| US-10975080-B2 | Compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2021-04-13 | — | — | US | disclosed |
| US-10975080-B2 | Compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2021-04-13 | — | — | US | disclosed |
| US-20190185475-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-06-20 | — | — | US | disclosed |
| US-20190185475-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-06-20 | — | — | US | disclosed |
| EP-3310779-B1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2019-05-08 | — | — | EP | disclosed |
| WO-2016203404-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089597-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | PTPN1, PTPN3, PTPN5 | ALDH1A1 3953/4885POLB 4349/4885MAPT 4320/4885 |
| US-10975080-B2 | Compounds and compositions for inhibiting the activity of SHP2 | PTPN1, PTPN3, PTPN5 | ALDH1A1 4341/4885POLB 4111/4885MAPT 4046/4885 |
| US-20190185475-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | PTPN1, PTPN3, PTPN5 | ALDH1A1 3953/4885POLB 4349/4885MAPT 4320/4885 |
| US-20210309663-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | PTPN1, PTPN3, PTPN5 | ALDH1A1 3953/4885POLB 4349/4885MAPT 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.